Chengda Bio

Liaoning Chengda Biotechnology Co., Ltd. (referred to as "Chengda Bio") was established in Shenyang in June 2002, taking the opportunity of introducing advanced vaccine production technology platforms. Adhering to the philosophy of "In the face of life, only responsibility" and upholding the core values of "Integrity and Responsibility", the company is dedicated to the research, development, production, and promotion of biological products that meet international standards and are world-leading, aiming to build itself into a highly respected and influential enterprise in the industry. Currently, it has a production capacity of over 40 million doses of human rabies vaccine and over 10 million doses of human inactivated Japanese encephalitis vaccine.
Through "introduction, digestion, absorption, and re-innovation", the company has mastered the "platform technology for large-scale vaccine production using bioreactors", overcoming the technical challenge that had plagued China for over a decade in large-scale animal cell culture for producing high-quality vaccines. The "Chengda Suda" human rabies vaccine produced using this technology has broken the long-term monopoly of multinational companies in China's high-end human rabies vaccine market. Its technical indicators have reached the advanced level of similar international products, and it has become the leading brand of human rabies vaccine in China. It has been exported to more than ten countries, including India, and is undergoing product registration in several countries such as Vietnam. To date, nearly 20 million people have been vaccinated with Chengda Suda human rabies vaccine, with no reported cases of immunization failure, making it the vaccine of choice for rabies prevention in China. The "Chengda Libao" human inactivated Japanese encephalitis vaccine, also produced using this technology, has achieved internationally advanced product quality and technical indicators, particularly being free of antibiotics and preservatives, which gives it strong international competitiveness. Since its market launch in 2008, its excellent safety has been welcomed by doctors and vaccine recipients, becoming the high-end vaccine for preventing Japanese encephalitis in Chinese children. Currently, the human inactivated Japanese encephalitis vaccine has obtained registration approval in Cambodia, and is undergoing product registration in several other countries, including India.
In addition, the company has developed a bivalent hemorrhagic fever with renal syndrome vaccine (Vero cell) that has obtained approval for phase III clinical trials; a veterinary rabies inactivated vaccine (PV2061) that has received the new drug certificate from the Ministry of Agriculture; and has achieved significant technical breakthroughs in its ongoing development of a human influenza vaccine (Vero cell). With subsequent products gradually entering the market, leveraging its leading technical indicators and product quality, they are expected to become new profit growth points for the company.
Chengda Bio is a leader in China's vaccine industry.